← Back to Search

Early Parkinson's disease for Multiple System Atrophy

N/A
Waitlist Available
Research Sponsored by Asklepios Biopharmaceutical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

Summary

The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

Eligible Conditions
  • Multiple System Atrophy
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MSA symptoms/signs as assessed by the Unified Multiple System Atrophy Rating Scale (UMSARS)
Motor symptoms as assessed by the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Secondary study objectives
Change in the quality of life as measured by Multiple System Atrophy Quality of Life (MSA-QoL)
Change in the quality of life as measured by Parkinson's Disease Questionnaire (PDQ-39)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Possible or Probable MSA-PExperimental Treatment1 Intervention
Group II: Early Parkinson's diseaseExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Asklepios Biopharmaceutical, Inc.Lead Sponsor
7 Previous Clinical Trials
283 Total Patients Enrolled
~44 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top